Devonian Health Group (GSD) Q2 2025 earnings summary

Executive summary

• Revenue for the second quarter increased 275% year over year, driven by the DEXLANSOPRAZOLE distribution agreement launched in 2024.

• Net loss narrowed significantly to $0.228 million ($0.001 per share) from $1.210 million ($0.01 per share) in the prior year quarter.

• All outstanding debt was repaid during the quarter, improving the financial position.

• Cash and cash equivalents stood at $8.4 million at quarter end.

Financial highlights

• Distribution revenue reached $8.28 million in Q2, up 275% year over year.

• Net loss for the quarter was $0.228 million, or $0.001 per share, compared to $1.210 million, or $0.01 per share, a year ago.

• Cash and cash equivalents were $8.4 million at January 31, 2025, with no debt, compared to $9.9 million cash and $2.1 million debt at the fiscal year's start.

Outlook and guidance

• Current liquidity is expected to support ongoing scientific progress and value creation over the next year, despite the upcoming expiration of the DEXLANSOPRAZOLE distribution agreement in April 2025.

• Management remains focused on advancing Thykamine™ and leveraging recent positive study results.